PPLPHARMA

1-day change: +3.44% 1-week: +2.6% 1-month: +3.8% 3-months: –5.4% 1-year: +37.5% Valuation stretched: Extremely high P/E (300×) suggests current price includes high growth expectations . Profitability concerns: Low ROE (1%) and high interest costs (4.6% of revenue) Sector performance mix: Up strongly over 1 year, but down short‑term due to broader pharma/capex cycle dynamics .